Koers Catabasis Pharmaceuticals Inc Nasdaq
Aandelen
US14875P1075
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 504 mln. 473 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -79 mln. -74,14 mln. | Nettowinst (verlies) 2025 * | -101 mln. -94,79 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-5,93
x | K/w-verhouding 2025 * |
-4,66
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 87,7% |
Recentste transcriptie over Catabasis Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jill Milne
FOU | Founder | 56 | 26-06-08 |
Noah Clauser
DFI | Director of Finance/CFO | 51 | 01-04-11 |
Chief Tech/Sci/R&D Officer | - | 15-07-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 01-01-14 |
Gregg Lapointe
BRD | Director/Board Member | 65 | 04-01-19 |
Director/Board Member | 75 | 05-04-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,46% | 102 mld. | |
+1,41% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-15,84% | 21,4 mld. | |
-9,21% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-14,65% | 16,09 mld. | |
+4,39% | 13,83 mld. | |
+31,35% | 11,97 mld. |